ctnm-20260626
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________
FORM 8-K
______________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2026
______________________________________________________________________
Contineum Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
______________________________________________________________________
| Delaware | 001-42001 | 27-1467257 | ||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
3565 General Atomics Court, Suite 200 San Diego, California | 92121 | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
(858) 333-5280
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
______________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Class A Common Stock, par value $0.001 per share | CTNM | The Nasdaq Global Market LLC (Nasdaq Global Select Market) | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 26, 2026, Contineum Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 27, 2026, the record date for the Annual Meeting, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote at the Annual Meeting. The Annual Meeting was conducted virtually, and the following is a brief summary of the matters voted upon by stockholders at the Annual Meeting.
Proposal 1: Election of Directors
The Company’s stockholders elected the three persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been elected or appointed. The final voting results are as follows:
| Director Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
| Evert Schimmelpennink | 21,773,559 | 131,384 | 6,133,812 | |||||||||||||||||
| Lori M. Lyons-Williams | 20,593,715 | 1,311,228 | 6,133,812 | |||||||||||||||||
| Diego Miralles, M.D. | 21,673,187 | 231,756 | 6,133,812 | |||||||||||||||||
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:
| Votes For | Votes Against | Votes Withheld | Broker Non-Votes | |||||||||||||||||
| 28,021,047 | 16,104 | 1,604 | N/A | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 26, 2026
| Contineum Therapeutics, Inc. | ||||||||
| By: | /s/ Peter Slover | |||||||
| Peter Slover | ||||||||
Chief Financial Officer Principal Financial Officer and Principal Accounting Officer | ||||||||